Navigation Links
Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes
Date:11/9/2012

research, and these results further support the efficacy and safety profile of canagliflozin," said Kirk Ways, M.D., Ph.D., Vice President and Compound Development Team Leader for canagliflozin at Janssen. "The data are in line with the Phase 3 results announced earlier this year at the annual meetings of the American Diabetes Association and European Association for the Study of Diabetes which suggest that canagliflozin could help control blood glucose in a wide range of patients with type 2 diabetes, including patients on other antihyperglycemic medications such as pioglitazone and metformin."

These results are included in the abstract, "Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes on Metformin and Pioglitazone" (board #64). An additional abstract, "Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes with Moderate Renal Impairment" (board #75) will also be presented at CODHy 2012.

About Canagliflozin

Canagliflozin is an investigational sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of patients with type 2 diabetes. The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to non-diabetic people, which may contribute to elevated glucose levels. Canagliflozin blocks the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels.

The global Phase 3 canagliflozin clinical program, which enrolled 10,285 patients in nine studies, is the largest late-stage development program for an investigational pharmacologic product for the treatment of type 2 diabetes submitted to health authorities to date. The program evaluated the safety and efficacy of canagliflozin across the spectrum of type 2 diabetes management, from adult patients treated only with diet and exercise to those requiring insulin injections to maintain glycemic control, and in three large studies in special populations: older p
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , 21. November 2014 Michael ... sich am Morgen des 14. Februar 2014 zugetragen hat. ... wohl kaum vergessen. Video - http://youtu.be/5cVoMCe0uiE ... ich dabei war, mein morgendliches Training zu machen", erzählt ... zu der Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. ...
(Date:11/21/2014)... Nov. 20, 2014 Oxis International, Inc. (OXIS) (OXI.PA) ... election of Anthony J. Cataldo as Chief Executive ... Effective November 19, 2014, Ken Eaton resigned his ... of Directors of Oxis International, Inc. to pursue new opportunities. ... named Chief Executive Officer of Oxis International, Inc. Mr. Cataldo ...
(Date:11/21/2014)... , Nov. 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... priced its offering of $80,000,000 aggregate principal amount of ... in a private offering within the United ... qualified institutional buyers pursuant to Rule 144A under the ... Lexicon has also granted the initial purchasers an option ...
Breaking Medicine Technology:Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 2DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 3DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 4DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 5DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 6DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 7Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 2Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 3Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 4Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 5Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 6Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 7Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 8Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 9Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 10Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 11
(Date:11/22/2014)... (PRWEB) November 22, 2014 A ... was announced today which safely detects and identifies ... frequency radio waves. Developed by RHT SpectraSafe, the ... hosts broad applications in other areas including medical, ... security. , Using high frequency radio waves that ...
(Date:11/22/2014)... DC (PRWEB) November 22, 2014 “Greenfield ... monthly Tech Report , which features the latest ... a technology expert and reporter for NewsWatch, conducted the ... easily improve the flavor of your water. , From ... everywhere. It’s important that everything is done to remove ...
(Date:11/22/2014)... OH (PRWEB) November 22, 2014 A Xarelto ... York woman who is seeking $10 million in damages from ... thinner . According to the lawsuit, the woman began using ... The woman alleges in her lawsuit she suffered life-threatening bleeding ... permanent personal injuries, pain, suffering and emotional distress. The lawsuit ...
(Date:11/22/2014)... 21, 2014 (HealthDay News) -- Many young people consider ... a new study finds fumes from the water pipes ... to an increased risk for leukemia in prior research, ... the journal Cancer Epidemiology, Biomarkers & Prevention . ... smoking is not a safe alternative to smoking other ...
(Date:11/22/2014)... By Steven Reinberg ... -- Stroke outcomes are better when patients are treated in ... and clot-busting drugs, German researchers report. The sooner patients ... the better the outcome after a stroke, the researchers noted. ... within the first hour after stroke symptoms start, the researchers ...
Breaking Medicine News(10 mins):Health News:RHT SpectraSafe announces a Radical New Airport Security Technology that Is More Effective, Less Invasive 2Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 4Health News:Hookahs Deliver Toxic Benzene in Every Puff, Study Shows 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... DETROIT, Dec. 10 African-American political leaders, union members, ... 14th to create and implement a strategy to ... , "Detroit is leading the nation in murders, ... Horace Sheffield III, National Board Member and Michigan Chapter ...
... Knowledge of regimen may help avert drug errors, study ... A small study finds that even adults who know ... the drugs they,re getting in the hospital. , Forty-four ... in the hospital that was not actually prescribed. A ...
... , ST. PAUL, Minn., Dec. 10 /PRNewswire-USNewswire/ ... Centers, will host their 6th annual blood drive event with ... drive, taking place at the St. Paul Donor Center (I-94 ... other players and cheerleaders scheduled to arrive around 2 PM. ...
... , Television, movie and music personalities urge people ... WASHINGTON, Dec. 10 A group of celebrities ... new American Red Cross holiday giving campaign and give a gift ... http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , Celebrity supporters of the Red Cross ...
... , Nearly 200 care providers face shutdowns, ... Illinois, seniors to fend for themselves , AARP, ... deal with the costly consequences of sending seniors to nursing ... of advocate organizations sounded the alarm on the consequences that ...
... a car tailpipe or factory smokestack affect climate and air ... until now, scientists have struggled to know where these organic ... their source, leading to models for predicting climate and air ... A major collaborative effort of more than 60 scientists led ...
Cached Medicine News:Health News:Black Community Unites Against HIV/AIDS Epidemic 2Health News:Most Hospital Patients Don't Know What Meds They're Taking 2Health News:Most Hospital Patients Don't Know What Meds They're Taking 3Health News:Minnesota Vikings Team With Memorial Blood Centers Again for Annual Blood Drive 2Health News:Entertainment Celebrities Support Red Cross Holiday Giving Campaign 2Health News:Entertainment Celebrities Support Red Cross Holiday Giving Campaign 3Health News:State $200 Million Behind in Payments to Agencies Providing Care to Thousands of Older Illinoisans 2Health News:New approach to emissions makes climate and air quality models more accurate, major study finds 2Health News:New approach to emissions makes climate and air quality models more accurate, major study finds 3
Inquire...
Holligard protects skin from irritating stomal discharge. Holligard is flexible and durable in heat and humidity....
Security and confidence assured with porous tape; integral deodorizing/venting filter....
Contour I pouches are light as a feather and feature our tapered SoftFlex skin barrier for comformability, flexbility and comfort. All Contour I pouches have ComfortWear panels that keep skin cool an...
Medicine Products: